iRhythm Holdings, Inc. has completed the acquisition of VitalConnect, Inc., a wearable biosensor technology company, according to a Form 8-K filed with the SEC on October 5, 2026. The transaction was executed by iRhythm Technologies, Inc., a direct wholly owned subsidiary of iRhythm.
The acquisition broadens iRhythm’s cardiac monitoring portfolio by adding VitalConnect’s capabilities in mobile cardiac telemetry (MCT) and multi-vitals monitoring. VitalConnect’s platform supports up to 30 days of patient monitoring and tracks up to 11 physiological parameters. The company stated that the combination will allow iRhythm to serve more clinicians and patients across the continuum of care, including inpatient, remote, and hospital-to-home settings.
The purchase consideration for the transaction consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm’s balance sheet. Additionally, the company issued up to 423,334 shares in connection with the closing. Between signing and closing, iRhythm provided $10.0 million of working capital funding to VitalConnect.
Following the closing, VitalConnect became a direct wholly owned subsidiary of iRhythm Technologies and an indirect wholly owned subsidiary of iRhythm Holdings. The combined entity is expected to enhance iRhythm’s revenue growth rate beginning in 2027 while preserving its previously communicated adjusted EBITDA margin target of 15% for 2027.
iRhythm plans to provide updated 2026 financial guidance, inclusive of VitalConnect, during its third quarter earnings call on November 5, 2026.
